Relay Therapeutics Reports First Quarter 2026 Financial Results and Corporate Updates
Relay Therapeutics ended Q1 2026 with $642.1 million in cash and investments, extending its runway into 2029 after raising $137.1 million via at-the-market offerings. The FDA granted Breakthrough Therapy designation to zovegalisib for 2L PIK3CA-mutant breast cancer, supported by data showing an 11.1-month median PFS in the ReDiscover-2 trial.
Key figures
- Revenue
- 3000000
- Net loss
- 73300000
- Pfs months
- 11.1
- Orr percent
- 44
- Rd expenses
- 70600000
- Cash balance
- 642100000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.